Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?

doi:10.4254/wjh.v7.i12.1606

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7178)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-8) series.

Item

Count

PDF

458

WORD

291

HTML

3055

Tables (1-8)

346

Sum=4150

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1270

Download

1758

Sum=3028

Jun 28, 2015 (publication date) through Mar 13, 2025

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Jun 28, 2015; 7(12): 1606-1616
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1606

Table 5 Treatment of hepatitis C virus recurrence post liver transplant

IFN-free: Sofosbuvir + RBV (HCV genotype 2 for 12-24 wk); sofosbuvir + daclatasvir ± RBV (HCV genotypes 1, 3-6 for 12-24 wk); sofosbuvir + simeprevir ± RBV (HCV genotypes 1, 4 for 12 -24 wk)
In case of restriction applying first generation DAAs
Fibrosis metavir stage 3-4	Genotype 2/3	Genotype 1
Genotype 1a		Fibrosis metavir stage 2
IL-28B polymorphism		Predictors of poor response
Fibrosing cholestatic hepatitis	Peg-IFN plus RBV	Peg-IFN plus RBV plus boceprevir or telaprevir
Non responders to previous treatments	Monitor closely Hb, WBC, PLTs CNI levels, renal function
	Consider
	Administration of blood transfusions, EPO, CSGF
	Decrease of RBV dose
	Renal dose adjustment
	Decrease of CNI dose

IFN: Interferon; RBV: Ribavirin; CNI: Calcineurin inhibitor; HCV: Hepatitis C virus; Peg-IFN: Pegylated interferon; DAA: Direct antiviral agent; WBC: White cells blood count; PLTs: Platelets; EPO: Erythropoietin; CSGF: Granulocyte-colony stimulating factor.

Citation: Pipili C, Cholongitas E. Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand? World J Hepatol 2015; 7(12): 1606-1616
URL: https://www.wjgnet.com/1948-5182/full/v7/i12/1606.htm
DOI: https://dx.doi.org/10.4254/wjh.v7.i12.1606